Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kumar Prabhash

Showing results (431-440 of 469) with videos related to

Pageof 47
Sort By:
Lancet (London, England)|July 9, 2023
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled studySiow Ming Lee, Christian Schulz, Kumar Prabhash, et al.
Future Oncology (London, England)|May 20, 2025
A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)Siow Ming Lee, Christian Schulz, Anne-Marie Baird, et al.
Cancers|January 28, 2026
Decoding Osteoradionecrosis of the Jaw: Radiological Progression and a Novel CT-Based Grading SystemVasundhara Patil, Pritesh Shah, Abhishek Mahajan, et al.
Journal of Geriatric Oncology|June 16, 2023
Validation of the Onco-MPI in predicting short-term mortality in older Indian patients with cancerRamnath Shenoy, Abhijith Rajaram Rao, Pallavi Pratisad Rane, et al.
South Asian Journal of Cancer|July 14, 2022
Ramucirumab in Indian Patients with Advanced Gastric Cancer-Does Borderline Performance Status and Heavy Burden of Disease in Real World Practice Impact Clinical Benefit?Anant Ramaswamy, Kripa Bajaj, Vineet Talwar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2022
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized StudyVijay Maruti Patil, Vanita Noronha, Nandini Menon, et al.
Eclinicalmedicine|May 31, 2019
Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung CancerVijay Patil, Vanita Noronha, Amit Joshi, et al.
JTO Clinical and Research Reports|January 31, 2024
A Comparative Study Evaluating the Quality of Life and Survival Outcomes in Patients Receiving Chemotherapy Versus Oral Tyrosine Kinase Inhibitor in the Third Line and Beyond Setting for Advanced NSCLCVanita Noronha, Nandini S Menon, Vijay Maruti Patil, et al.
JAMA Network Open|August 6, 2024
Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy: A Phase 3 Randomized Clinical TrialVikas Ostwal, Anant Ramaswamy, Sarika Mandavkar, et al.
Lancet (London, England)|June 17, 2014
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialEdward B Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, et al.
Pageof 47

Showing results (431-440 of 469) with videos related to

Sort By:
Pageof 47
Lancet (London, England)|July 9, 2023
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled studySiow Ming Lee, Christian Schulz, Kumar Prabhash, et al.
Future Oncology (London, England)|May 20, 2025
A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)Siow Ming Lee, Christian Schulz, Anne-Marie Baird, et al.
Cancers|January 28, 2026
Decoding Osteoradionecrosis of the Jaw: Radiological Progression and a Novel CT-Based Grading SystemVasundhara Patil, Pritesh Shah, Abhishek Mahajan, et al.
Journal of Geriatric Oncology|June 16, 2023
Validation of the Onco-MPI in predicting short-term mortality in older Indian patients with cancerRamnath Shenoy, Abhijith Rajaram Rao, Pallavi Pratisad Rane, et al.
South Asian Journal of Cancer|July 14, 2022
Ramucirumab in Indian Patients with Advanced Gastric Cancer-Does Borderline Performance Status and Heavy Burden of Disease in Real World Practice Impact Clinical Benefit?Anant Ramaswamy, Kripa Bajaj, Vineet Talwar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2022
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized StudyVijay Maruti Patil, Vanita Noronha, Nandini Menon, et al.
Eclinicalmedicine|May 31, 2019
Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung CancerVijay Patil, Vanita Noronha, Amit Joshi, et al.
JTO Clinical and Research Reports|January 31, 2024
A Comparative Study Evaluating the Quality of Life and Survival Outcomes in Patients Receiving Chemotherapy Versus Oral Tyrosine Kinase Inhibitor in the Third Line and Beyond Setting for Advanced NSCLCVanita Noronha, Nandini S Menon, Vijay Maruti Patil, et al.
JAMA Network Open|August 6, 2024
Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy: A Phase 3 Randomized Clinical TrialVikas Ostwal, Anant Ramaswamy, Sarika Mandavkar, et al.
Lancet (London, England)|June 17, 2014
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialEdward B Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, et al.
Pageof 47